Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
01:53:31 EDT Sat 16 May 2026
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:CYTK - CYTOKINETICS INC - https://www.cytokinetics.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CYTK - Q0.174.40·77.400.175.85-2.79-3.51,829.8138,10816,02478.40  78.51  75.4880.20  29.7519:22:47May 1415 min RT 2¢

Recent Trades - Last 10 of 16024
Time ETExPriceChangeVolume
19:22:47Q75.67-2.9792
19:20:56Q75.85-2.798
19:08:56Q75.85-2.791
19:08:56Q75.85-2.791
16:56:41Q75.6485-2.99151
16:27:52Q75.62-3.022
16:24:20Q75.61-3.031
16:10:29Q75.85-2.795,941
16:10:05Q75.85-2.791
16:10:05Q75.85-2.791

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-05-14 07:30U:CYTKNews ReleaseCytokinetics to Host Annual Symposium on Contemporary Landscapes in Muscle Biology (CLIMB)
2026-05-12 16:00U:CYTKNews ReleaseCytokinetics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
2026-05-11 10:06U:CYTKNews ReleaseCytokinetics Announces New Data Related to MYQORZO(TM) (aficamten) at ESC Heart Failure 2026
2026-05-08 10:52U:CYTKNews ReleaseCytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $805 Million
2026-05-06 23:00U:CYTKNews ReleaseCytokinetics Announces Pricing of Upsized Public Offering of Common Stock
2026-05-05 16:15U:CYTKNews ReleaseCytokinetics Announces Proposed Public Offering of Common Stock
2026-05-05 16:05U:CYTKNews ReleaseCytokinetics Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-05 07:30U:CYTKNews ReleaseCytokinetics Announces Positive Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy
2026-05-04 16:00U:CYTKNews ReleaseCytokinetics to Announce Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy, on May 5, 2026
2026-04-28 07:30U:CYTKNews ReleaseCytokinetics Announces Nine Upcoming Presentations at the European Society of Cardiology Heart Failure 2026 Congress
2026-04-21 16:00U:CYTKNews ReleaseCytokinetics to Announce First Quarter Results on May 5, 2026
2026-04-20 16:00U:CYTKNews ReleaseCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2026-04-06 16:00U:CYTKNews ReleaseCytokinetics to Participate in the 25th Annual Needham Virtual Healthcare Conference
2026-03-18 16:00U:CYTKNews ReleaseCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2026-03-16 08:00U:CYTKNews ReleaseCytokinetics Announces Four Presentations at the American College of Cardiology Annual Scientific Session & Expo
2026-03-02 16:00U:CYTKNews ReleaseCytokinetics to Participate in March Investor Conferences
2026-02-24 16:00U:CYTKNews ReleaseCytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update
2026-02-17 07:30U:CYTKNews ReleaseCytokinetics Announces European Commission Approval of MYQORZO(TM) (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
2026-02-12 16:00U:CYTKNews ReleaseCytokinetics to Announce Fourth Quarter Results on February 24, 2026
2026-02-09 07:30U:CYTKNews ReleaseCytokinetics Announces Recipients of Its Eighth Annual Communications Grant Program